Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin

Acta Paediatrica, International Journal of Paediatrics

Volumn 94, Issue 12, 2005, Pages 1738-1741

  Anbu, Anbarasu Theodore ^a   Kemp, Timothy ^a   O'Donnell, Kate ^a   Smith, Patricia A ^a   Bradbury, Mark G ^a  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Adverse events; Anaemia; Chronic renal failure; Intravenous iron; Iron sucrose

Indexed keywords

ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE;

ABDOMINAL PAIN; ADOLESCENT; ANEMIA; ARTICLE; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DRUG INFUSION; HEMODIALYSIS; HUMAN; HYPERTENSION; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; OBSERVATIONAL STUDY; OUTPATIENT; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; SMELLING DISORDER; TASTE DISORDER; VASCULAR ACCESS; VEIN; VOMITING;

ANEMIA; CHILD; ERYTHROPOIETIN, RECOMBINANT; FERRIC COMPOUNDS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; PROSPECTIVE STUDIES;

EID: 31544444203     PISSN: 08035253     EISSN: 15023869     Source Type: Journal    
DOI: 10.1080/08035250500281921     Document Type: Article

References (10)

1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anaemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
2. Tentbrock K, Muller-Berghaus J, Michalk D, Querfeld U. Intravenous iron treatment of renal anemia in children on haemodialysis. Pediatr Nephrol 1999;13:580-2.
3. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int 1999;69 Suppl 55:61-6.
4. Allegra V, Mengozzi G, Martimbianco L, Vasile A. Iron deficiency in maintenance haemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 1991;57:175-82.
5. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomised controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-9.
6. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextran. Am J Kidney Dis 1999;33:464-70.
7. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM. A randomised controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEPO. Nephrol Dial Transplant 2001;16:1239-44.
8. Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000;36:88-97.
9. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 2001;38:988-91.
10. Macdougall IC, Bailie G, Richardson D. Worldwide safety profile of iron sucrose injection (Venofer®): Analysis of 1,004,477 patients from 1992 to 2001. Presented at: ASN World Congress of Nephrology, October 13-17, 2001. San Francisco, CA.